Why invest in BlinkLab?
BlinkLab combines proprietary technology, clinical validation studies, and a clear, staged regulatory pathway to commercialization, addressing an unmet medical need in autism assessment.
Unmet medical need
Given the clear gap in the autism evaluation process, BlinkLab is developing a product that brings objective measurement into clinician-led assessment.
The problem
Autism evaluations remain clinician-led and observation-based, and therefore inherently subjective, leading to variability across clinicians and sites. The lack of objective measures in the evaluation process creates an unmet medical need. That leaves specialists reliant on observation-based assessment alone and contributes to later, less accurate autism identification.
The opportunity
BlinkLab is addressing this unmet medical need by bringing objective, reflex-based measures into clinician-led, observation-based autism assessment through an AI-powered, smartphone-based diagnostic tool that can be used in a comfortable at-home setting. By reducing reliance on observation-based assessment alone, BlinkLab’s approach is designed to help specialists identify autism earlier and more accurately.
Scalable technology platform
A software-as-a-medical-device platform designed to support clinical validation, regulatory approval and post-authorization use.
Technology platform
BlinkLab has developed a proprietary smartphone-based platform using computer vision and machine learning to analyze behavioral markers relevant to pediatric neurological assessment. The platform is designed to support multiple diagnostic indications.
Intellectual property
BlinkLab’s technology is supported by proprietary algorithms, datasets and software architecture, providing a foundation for ongoing product development and protection.
Why invest in BlinkLab?
BlinkLab’s approach pursues more equitable access to neurodevelopmental assessments as a part of critical changes in healthcare. Our flagship technology combines the accessibility of a smartphone with AI and machine learning technologies to enable more scalable and objective assessments.
Proprietary and unique technology with objective, reflex-based measurement
An AI-powered neuroscientific diagnostic tool designed to support clinical observation and enable earlier and more accurate autism identification
Scalable technology platform
A smartphone-based process with comfortable at-home use, built for quick deployment across sites
Clinical validation
BlinkLab Dx 1 pilot study results and an FDA 510(k) pivotal study underway with leading U.S. autism research centers
Scientific validation
Peer-reviewed journal publications supporting BlinkLab’s technology platform and approach
Strategic partnerships
Clinical, academic, and commercial collaborations with leading institutions to strengthen the product
Clear regulatory pathway to commercialization
A defined, staged approach toward meeting FDA requirements for software as a medical device (SaMD)
Clear pathway to commercialization
BlinkLab’s product pipeline reflects a staged approach to clinical validation for autism and ADHD, regulatory engagement, and post-authorization monitoring, enabling commercialization in line with FDA requirements for software as a medical device (SaMD).
BlinkLab’s product pipeline reflects a staged approach to clinical validation for autism and ADHD, regulatory engagement, and post-authorization monitoring, enabling commercialization in line with FDA requirements for software as a medical device (SaMD).